Anixa Biosciences rises after Mexico approves patent for breast cancer vaccine

Shares of San Jose-based cancer treatment developer Anixa Biosciences ANIX.O up 7.47% at $3.32 premarket

Co says Mexican Institute of Industrial Property approved a patent for its experimental breast cancer vaccine

The vaccine aims to train the immune system to target a protein linked to tumor formation, co says

"The Mexican patent complements patents issued in the United States and other key global jurisdictions, and represents an important step toward future regulatory and commercial efforts outside the U.S.," says co

Vaccine technology was developed at U.S. medical research center Cleveland Clinic and is licensed exclusively to Anixa

Shares up ~34% in 2025